Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
- Reimbursement of Generic Drugs Used Off-Label “Not Necessarily Illegal,” Government Says
September 20, 2012
- Half of Hospitals Participating in Network Play Central Role: MHLW FY2011 Survey
September 19, 2012
- MHLW Eyes Introduction of Piecework Payment for Clinical Trials at 54 Hospitals by FY2016
September 18, 2012
- MHLW Budget Request Includes Funds for Database of Information on Patients with Cancer, Lifestyle Diseases
September 18, 2012
- MHLW Calls for Self-Inspections at Japanese Pharmaceutical Firms after “Gutter Oil”-Made Antibiotic Intermediates Found in China
September 14, 2012
- MHLW Instructs Daiichi Sankyo to Issue Blue Letter on Ranmark Following Two Reported Deaths
September 13, 2012
- MEXT Calls for 21 Billion Yen for Special Priority Area of Healthcare Innovation in FY2013 Budget Request
September 12, 2012
- Osaka District Court to Issue Ruling on Actos Patent Suit on Sept. 27
September 12, 2012
- MHLW Issues Q&As on Drug Risk Management Plans to Prefectures
September 12, 2012
- MHLW Notifies of Expected Additional Indications for 3 APIs
September 12, 2012
- PAFSC’s 2nd Committee Designates 7 products as Orphan Drugs Including Glioblastoma Treatment Bevacizumab
September 11, 2012
- Chairman Breaks Tie, Votes to Continue Lower House Discussions on Bill to Establish 3rd-Party Organization
September 11, 2012
- MHLW’s FY2013 Budget Request Includes Funding to Set Up Municipal Generic Drug Promotion Councils
September 11, 2012
- PAFSC 2nd Committee Recommends Approval for Novartis’s COPD Drug
September 11, 2012
- DPJ’s Project Team Concerned that Participation in TPP Agreement Could Interfere with Japan’s Industrial Policies
September 10, 2012
- MHLW to Study Overseas Generic Drug Markets to Support Globalization of Domestic Industry
September 10, 2012
- “Some Problems” Found with UMN Pharma’s Cell Culture Method Development Project: MHLW
September 7, 2012
- Labor Standards Bureau Head Junichi Kaneko to Be Appointed Vice Minister of Health; Pension Bureau Head Jun Ebata to Be Transferred to PFSB: MHLW
September 6, 2012
- MHLW to Request 41.1 Bil. Yen in FY2013 Budget for Drug Discovery Support and Other Special Priority Projects
September 6, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…